The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
Open Access
- 1 July 2024
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 44 (10) , 2538-2550
Abstract
Background and Aims: We examined the impact of a co‐diagnosis of metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) on patient outcomes.Methods: Using TriNetX, a global federated research network (n = 114 million), we undertook two retrospective cohort studies, using time‐to‐event analysis. Analysis 1 compared MASLD with T2D to MASLD alone; analysis 2 compared T2D with MASLD to T2D alone. Propensity score matching using greedy nearest neighbour (calliper .1) balanced the cohorts (1:1) for significant covariates. Primary outcomes were cardiovascular, liver, diabetes‐related, and cancer events over 5 years.Results: Analysis 1 (n = 95 275): a co‐diagnosis of T2D significantly increased the risk of ischaemic heart disease (IHD) (HR 1.39; CI: 1.34, 1.44), ischaemic stroke (HR 1.45; CI: 1.35, 1.56), heart failure (HR 1.42; CI: 1.36, 1.49), atrial fibrillation (HR 1.09; CI: 1.03, 1.16), hepatocellular carcinoma (HR 1.96; CI: 1.69, 2.27), pancreatic cancer (HR 1.25; CI: 1.06, 1.48) and liver‐related complications over 5 years from MASLD diagnosis. Analysis 2 (n = 15 208): a co‐diagnosis of MASLD significantly increased risk of all‐cause mortality (HR 1.11; CI: 1.02, 1.22), IHD (HR 1.181; CI: 1.08, 1.29), hepatocellular (HR 50.31; CI: 6.94, 364.72), pancreatic (HR 1.78; CI: 1.12, 2.84), breast (HR 1.43; CI: 1.09, 1.88) and renal cancer (HR 2.01; CI: 1.24, 3.26), and diabetic neuropathy (HR 1.17; CI: 1.09, 1.27) over 5 years from metformin initiation.Conclusions: T2D significantly potentiates the risk of cardiovascular, malignancy and liver‐related outcomes in people with MASLD. The effect of MASLD on people with T2D, although less dramatic, still potentiated risk of death, IHD, malignancy and peripheral neuropathy.Keywords
This publication has 35 references indexed in Scilit:
- Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort studyDiabetologia, 2023
- Global burden of liver disease: 2023 updateJournal of Hepatology, 2023
- The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall SurvivalClinical Therapeutics, 2022
- The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular RiskCurrent Diabetes Reports, 2021
- NAFLD and cardiovascular diseases: a clinical reviewClinical Research in Cardiology, 2020
- NAFLD as a driver of chronic kidney diseaseJournal of Hepatology, 2020
- Gamma-glutamyltransferase and risk of chronic kidney disease: A prospective cohort studyClinica Chimica Acta, 2017
- Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year‐community studyHepatology, 2017
- Prevalence of and Risk Factors for Nonalcoholic Fatty Liver Disease: The Dionysos Nutrition and Liver Study * #Hepatology, 2005
- The Natural History of Nonalcoholic Steatohepatitis: A Follow–Up Study of Forty–Two Patients for Up to 21 YearsHepatology, 1990